The Clinical Course of Renal Disease in Caucasian NIDDM-Patients

  • Søren Nielsen
  • Anita Schmitz


Diabetic nephropathy is now the most prevalent cause of end-stage renal disease (ESRD) in the western world [1], accounting for approximately 30% of all patients entering end-stage renal failure programmes [2]. Albeit diabetes is the single most important cause of ESRD in the United States [3], the percentage of patients with diabetes requiring renal replacement therapy in the European population is somewhat lower [4], about 13 % , leaving glomerulonephritis and renal vascular disease due to hypertension as the most frequent causes of ESRD [5]. Approximately one-half of the diabetes related ESRD occur in NIDDM patients [6,7].


Diabetic Nephropathy Renal Replacement Therapy Urinary Albumin Excretion Diabetes Duration Renal Plasma Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    FitzSimmons SC, Agodoa L, Striker L, Conti F, Striker G: Kidney disease of diabetes mellitus. NIDDK initiatives for the comprehensive study of its natural history, pathogenesis, and prevention. Am J Kidney Dis 1989; 8: 7–10.Google Scholar
  2. 2.
    Eggers PW. Effect of transplantation on the medicare end-stage renal disease program. N Engl J Med 1993; 381: 223–229.Google Scholar
  3. 3.
    Walker WG. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164–173.PubMedGoogle Scholar
  4. 4.
    Raine AEG. Epidemiology, development and treatment of end-stage renal failure in Type 2 (non-insulin-dependent) diabetic patients in Europe. Diabetologia 1993; 36: 1099–1104.PubMedCrossRefGoogle Scholar
  5. 5.
    Brunner FP, Selwood NH. Profile of patients on RRT in Europe and death rates due to major causes of death groups. Kidney Int 1992; 42: suppl. 38: S4–S15.Google Scholar
  6. 6.
    Rettig B, Teutsch SM. The incidence of end-stage renal disease in type II and type II diabetes mellitus. Diabetic Nephropathy 1984; 3: 26–27.Google Scholar
  7. 7.
    Grenfell A, Bewick M, Parsons V, Snowden S, Taube D, Watkins PJ. Non-insulin-dependent diabetes and renal replacement therapy. Diabetic Med 1988; 5: 172–176.PubMedCrossRefGoogle Scholar
  8. 8.
    Mogensen CE, Damsgaard EM, Frøland A, Nielsen S, de Fine Olivarius N, Schmitz A. Microalbuminuria in non-insulin-dependent diabetes. Clin Nephrol 1992; 38: suppl. 1: S28–S38.Google Scholar
  9. 9.
    Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356–360.PubMedCrossRefGoogle Scholar
  10. 10.
    Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non-insulin-dependent diabetics. Diabetic Med 1984; 1: 17–19.PubMedCrossRefGoogle Scholar
  11. 11.
    Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabetic Med 1988; 5: 126–134.PubMedCrossRefGoogle Scholar
  12. 12.
    Nelson RG, Pettitt DJ, Carraher MJ, Baird HR, Knowler W. Effect of proteinuria on mortality in NIDDM. Diabetes 1988; 37: 1499–1504.PubMedCrossRefGoogle Scholar
  13. 13.
    Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 1972; 30: 271–274.PubMedCrossRefGoogle Scholar
  14. 14.
    Bröchner-Mortensen J, Rødbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Mogensen CE, Hansen KW, Nielsen S, Mau Pedersen M, Rehling M, Schmitz A. Monitoring diabetic nephropathy: Glomerular filtration rate and abnormal albuminuria in diabetic renal disease — reproducibility, progression, and efficacy of antihypertensive intervention. Am J Kidney Dis 1993; 22: 174–187.PubMedGoogle Scholar
  16. 16.
    Vora JP, Dolben J, Dean JD, Thomas D, Williams JD, Owens DR, Peters JR. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int 1992; 41: 829–835.PubMedCrossRefGoogle Scholar
  17. 17.
    Schmitz A, Hansen HH, Christensen T. Kidney function in newly diagnosed type 2 (non-insulin- dependent) diabetic patients, before and during treatment. Diabetologia 1989; 32: 434–439.PubMedCrossRefGoogle Scholar
  18. 18.
    Damsgaard EM, Mogensen CE. Microalbuminuria in elderly hyperglycaemic patients and controls. Diabetic Med 1986; 3: 430–435.PubMedCrossRefGoogle Scholar
  19. 19.
    Myers BD, Nelson RG, Williams GW, Bennett PH, Hardy SA, Berg RL, Loon N, Knowler WC, Mitch WE. Glomerular function in Pima Indians with non-insulin-dependent diabetes mellitus of recent onset. J Clin Invest 1991; 88: 524–530.PubMedCrossRefGoogle Scholar
  20. 20.
    Palmisano JJ, Lebovitz HE. Renal function in black Americans with type II diabetes. J Diabetic Complications 1989; 3: 40–44.CrossRefGoogle Scholar
  21. 21.
    Vora JP, Dolben J, Williams JD, Peters JR, Owens DR. Impact of initial treatment on renal function in newly-diagnosed Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 734–740.PubMedCrossRefGoogle Scholar
  22. 22.
    Schmitz A, Christensen T, Jensen FT. Glomerular filtration rate and kidney volume in normoalbuminuric non-insulin-dependent diabetics — lack of glomerular hyperfiltration and renal hypertrophy in uncomplicated NIDDM. Scand J Clin Lab Invest 1989; 48: 103–108.CrossRefGoogle Scholar
  23. 23.
    Schmitz A, Christensen T, Møller A, Mogensen CE. Kidney function and cardiovascular risk factors in non-insulin- dependent diabetics (NIDDM) with microalbuminuria. J Intern Med 1990; 228: 347–352.PubMedCrossRefGoogle Scholar
  24. 24.
    Fabre J, Balant LP, Dayer PG, Fox HM, Vernet AT. The kidney in maturity onset diabetes mellitus: A clinical study of 510 patients. Kidney Int 1982; 21: 730–738.PubMedCrossRefGoogle Scholar
  25. 25.
    Silveiro SP, Friedman R, Gross JL. Glomerular hyperfiltration in NIDDM patients without overt proteinuria. Diabetes Care 1993; 16: 115–119.PubMedCrossRefGoogle Scholar
  26. 26.
    Nielsen S, Schmitz A, Rehling M, Mogensen CE. Systolic blood pressure relates to the rate of decline of glomerular filtration rate in Type 2 diabetes mellitus. Diabetes Care 1993; 16: 1427–1432.PubMedCrossRefGoogle Scholar
  27. 27.
    Gall M-A, Nielsen FS, Smidt UM, Parving H-H. The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 1993; 36: 1071–1078.PubMedCrossRefGoogle Scholar
  28. 28.
    Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol 1976; 31: 155–163.PubMedCrossRefGoogle Scholar
  29. 29.
    Ravid M, Savin H, Lang R, Jutrin I, Shoshana L, Lishner M. Proteinuria, renal impairment, metabolic control, and blood pressure in type 2 diabetes mellitus. Arch Intern Med 1992; 152: 1225–1229.PubMedCrossRefGoogle Scholar
  30. 30.
    Baba T, Murabayashi S, Tomiyama T, Takebe K. Uncontrolled hypertension is associated with a rapid progression of nephropathy in type 2 diabetic patients with proteinuria and preserved renal function. Tohoku J Exp Med 1990; 161: 311–318.PubMedCrossRefGoogle Scholar
  31. 31.
    Stornello M, Valvo EV, Scapellato L. Angiotensin converting enzyme inhibition in normotensive type II diabetics with persistent mild proteinuria. J Hypertens 1989; 7: suppl. 6: 314–315.Google Scholar
  32. 32.
    Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M, Shitrit A, Fuchs Z. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985; 75: 809–817.PubMedCrossRefGoogle Scholar
  33. 33.
    Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.PubMedCrossRefGoogle Scholar
  34. 34.
    DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovasculardisease. Diabetes Care 1991; 14: 173–194.CrossRefGoogle Scholar
  35. 35.
    Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ 1991; 302: 210–216.CrossRefGoogle Scholar
  36. 36.
    Gambardella S, Frontoni S, Lala A, Felici MG, Spallone V, Scoppola A, Jacoangeli F, Menzinger G. Regression of microalbuminuria in type II diabetic hypertensive patients after long-term indapamide treatment. Am Heart J 1991; 122: 1232–1238.PubMedCrossRefGoogle Scholar
  37. 37.
    Lacourcière Y, Nadeau A, Poirier L, Tancrède G. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993; 21: 786–794.PubMedCrossRefGoogle Scholar
  38. 38.
    Stornello M, Valvo EV, Vasques E, Leone S, Scapellato L. Systemic and renal effects of chronic angiotensin converting enzyme inhibition with captopril in hypertensive diabetic patients. J Hypertens 1989; 7: suppl. 7: 65–67.Google Scholar
  39. 39.
    Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. Comparison of enalapril and nifedipin in treating non-insulin dependent diabetes associated with hypertension: one year analysis. BMJ 1992; 305: 981–985.PubMedCrossRefGoogle Scholar
  40. 40.
    Valvo E, Bedogna V, Casagrande P, Antiga L, Zamboni M, Bommartini F, Oldrizzi L, Rugiu C, Maschio G. Captopril in patients with type II diabetes and renal insufficiency: Systemic and renal hemodynamic alterations. Am J Med 1988; 85: 344–348.PubMedCrossRefGoogle Scholar
  41. 41.
    Stornello M, Valvo EV, Scapellato L. Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and β-adrenoceptor blockers. Clin Sci 1992; 82: 19–23.PubMedGoogle Scholar
  42. 42.
    Baba T, Murabayashi S, Takebe K. Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: a randomised controlled trial. Diabetologia 1989; 32: 40–44.PubMedGoogle Scholar
  43. 43.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.PubMedCrossRefGoogle Scholar
  44. 44.
    Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 11: 1309–1311.CrossRefGoogle Scholar
  45. 45.
    Kostner GM, Karadi I. Lipoprotein alterations in diabetes mellitus. Diabetologia 1988; 31: 717–722.PubMedCrossRefGoogle Scholar
  46. 46.
    Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Voutilainen E, Penttila I, Pyörala K. Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1990; 33: 237–243.PubMedCrossRefGoogle Scholar
  47. 47.
    Nielsen S, Schmitz O, Møller N, Pørksen N, Klausen IC, Alberti KGMM, Mogensen CE. Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 1079–1086.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Søren Nielsen
  • Anita Schmitz

There are no affiliations available

Personalised recommendations